Medical

Following an advice meeting with the Paul Erhlich Institute, Israeli biopharm company BiondVax Pharmaceuticals announced plans for development of its lead candidate, an inhaled COVID-19 nanosized antibody (NanoAb) therapy. The company said that it hopes to initiate a Phase 1/2a clinical trial of the inhaled NanoAb in COVID-19 patients in 2023, following completion of … [Read more...] about BiondVax announces development plans for inhaled NanoAb for COVID-19

SoftOx Solutions has announced that a Phase 1 study of its SoftOx inhalation solution (SIS) demonstrated that nebulized SIS was well tolerated with no serious adverse effects observed and no adverse effects related to pulmonary function. The study enrolled 57 healthy volunteers who got either SIS or placebo delivered via jet nebulizer 4 times per day for 5 days, with … [Read more...] about SoftOx reports positive Phase 1 results for its hypochlorous acid inhalation solution

Pneumagen has announced that a Phase 1 dose escalation study of its Neumifil carbohydrate binding module nasal spray demonstrated that the nasal spray was well tolerated and had no dose limiting toxicity. Pneumagen announced the initiation of the Phase 1 trial in November 2021. The company previously announced data from pre-clinical studies showing that Neumifil has … [Read more...] about Positive Phase 1 results for Pneumagen’s Neumifil antiviral nasal spray

According to Opiant Pharmaceuticals, a pharmacodynamic study of the company's OPNT003 intranasal nalmefene met its primary endpoint of non-inferiority compared to intranasal naloxone, with 3 mg of OPNT003 almost twice as effective as 4 mg of naloxone in reversing respiratory depression caused by a synthetic opioid at 5 minutes post dose. OPNT003, which is … [Read more...] about PD study of Opiant’s intranasal nalmefene meets primary endpoint

Virpax Pharmaceuticals said that nasal delivery of its VRP324 dry powder cannabidiol in a rodent model produced high concentrations of CBD in the brain. In September 2021, Virpax announced that it had licensed Nanomerics’s molecular envelope technology (MET) for use with VRP324 and that Nanomerics was conducting preclinical studies. Virpax, which is developing the … [Read more...] about Virpax reports successful nose-to-brain delivery in a study of VRP324 dry powder CBD in a rodent model

Australian pharmaceutical company Firebrick Pharma has announced the initiation of a Phase 2 trial of its Nasodine povidone-iodine nasal spray for the reduction of viral shedding in patients with COVID-19. According to Firebrick, a 2001 pilot study with 6 COVID-19 patients demonstrated that a single dose of Nasodine reduced viral shedding by almost 80% one hour post … [Read more...] about Firebrick Pharma initiates Phase 2 trial of Nasodine povidone-iodine nasal spray for COVID-19

Researchers from Rensselaer Polytechnic Institute (RPI) and Albany Medical College will use a $500,000 grant from the New York State Biodefense Commercialization Fund for early development of a pentosan polysulfate (PPS) nasal spray for the prevention of respiratory infections, including COVID-19. PPS is currently approved in the US as an oral treatment for bladder … [Read more...] about Rensselaer and Albany Medical College get funding for development of pentosan polysulfate nasal spray against COVID-19